AbbVie 2014 Annual Report Download - page 36

Download and view the complete annual report

Please find page 36 of the 2014 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 182

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182

13MAR201512001133
13NOV201221352027
$100
$125
$150
$175
$225
$200
1/2/2013 6/30/2013 12/31/2013 6/30/2014 12/31/2014
AbbVie Inc. S&P 500 Index NYSE Arca PharmaceuƟcal Index
This performance graph is furnished and shall not be deemed ‘‘filed’’ with the SEC or subject to
Section 18 of the Exchange Act of 1934, nor shall it be deemed incorporated by reference in any of our
filings under the Securities Act of 1933, as amended.
Issuer Purchases of Equity Securities
(c) Total
Number of
Shares (or Units)
(a) Total Purchased as Part (d) Maximum Number (or
Number (b) Average of Publicly Approximate Dollar Value) of
of Shares Price Announced Shares (or Units) that May
(or Units) Paid per Share Plans or Yet Be Purchased Under the
Period Purchased (or Unit) Programs Plans or Programs
October 1, 2014 - October 31, 2014 9,410(1) $39.55 — $5,000,000,000(2)
November 1, 2014 - November 30,
2014 34,295(1) $51.43 — $5,000,000,000(2)
December 1, 2014 - December 31,
2014 4,513,139(1) $67.03 4,475,247 $4,699,938,463(2)
Total 4,556,844(1) $66.86 4,475,247 $4,699,938,463(2)
(1) These shares represent:
(i) the shares deemed surrendered to AbbVie to pay the exercise price in connection with the
exercise of employee stock options—9,410 in October; 34,295 in November; and 15,871 in
December; and
(ii) the shares purchased on the open market for the benefit of participants in the AbbVie Employee
Stock Purchase Plan—0 in October; 0 in November; and 22,021 in December.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding
obligations in connection with the vesting of restricted stock or restricted stock units. This
authorization supersedes the previously-disclosed $1.5 billion stock repurchase program.
(2) On October 20, 2014, AbbVie announced that its board of directors authorized the purchase of up to
$5.0 billion of its common stock, from time to time.
30 2014 Form 10-K
COMPARISON OF CUMULATIVE TOTAL RETURN